TICKERNERD
Menu
CRDFCRDFHealthcare · Biotechnology

CRDF Stock Forecast: Cardiff Oncology, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$0.91
+1.33% on the day

The 6 Wall Street analysts covering Cardiff Oncology, Inc. hold a median 12-month price target of $6.75 — +640.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 28 Oct 2026 — in the lower half.

Market cap
$73.1M
Ticker Nerd rank
48/ 100
Median analyst target
$6.75
Analysts covering
6
Revenue$104K−14.0% y/y
Operating income−$9.6M
Net income−$9.2M
Free cash flow−$11.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−22.1%
YTD
−67.5%
1Y
−59.3%
From 52W high
−71.6%
From 52W low
+14.0%
$0.80
$3.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRDF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cardiff Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
48/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
89
Size
78
Revisions
73
Issuance
63
Accruals
59
Volatility
23
Value
18
Momentum
17
Quality
16

Growth (89): Sales and profits are climbing, and climbing faster than before.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CRDF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRDF, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26CRDFHigh $12.00Median $6.75Low $1.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
3 Buy3 Hold0 Sell
Low $1.20Median $6.75High $12.00

The green dot is the last close — the median target sits +640.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Sept 2026HC Wainwright & Co.UpgradeBuy$9.00
12 Aug 2026William BlairDowngradeMarket Perform—
12 Aug 2026William BlairDowngradeMarket Perform—
3 June 2026Craig-HallumDowngradeHold$10 → $2.00
3 June 2026Craig-HallumDowngradeHold—
1 June 2026HC Wainwright & Co.DowngradeNeutral—
1 June 2026HC Wainwright & Co.DowngradeNeutral—
1 June 2026TD CowenDowngradeHold—
1 June 2026TD CowenDowngradeHold—
25 Feb 2026Piper SandlerMaintainsOverweight—
28 Jan 2026HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025HC Wainwright & Co.MaintainsBuy—
8 July 2025Ladenburg ThalmannInitiatesBuy—
24 June 2025JefferiesInitiatesHold—
9 May 2025HC Wainwright & Co.MaintainsBuy—
28 Feb 2025HC Wainwright & Co.MaintainsBuy—
13 Dec 2024Piper SandlerMaintainsOverweight—
8 Nov 2024HC Wainwright & Co.MaintainsBuy—
6 Sept 2024Craig-HallumInitiatesBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CRDF appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CRDF vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Cardiff Oncology, Inc. returned −59.3% against +13.1% for the S&P 500, dividends included.

CRDF vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26CRDFS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRDF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Cardiff Oncology, Inc. (CRDF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 85% of US stocks

Price / sales
143.8×

Cheaper than 3% of US stocks

Price / book
2.4×

Cheaper than 37% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−14.1%

Higher than 13% of US stocks

Earnings growth (YoY)
−14.0%

Higher than 24% of US stocks

Gross margin
—
Operating margin
−9245.2%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−94.1%

Higher than 14% of US stocks

Return on assets
−46.7%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cardiff Oncology, Inc. (CRDF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cardiff Oncology, Inc. has a market value of $73.1M and an enterprise value of $39.0M.

  • Revenue in the twelve months to 30 June 2026: $508K. The latest quarter shrank 14.1% year on year.

  • Net income over the same four quarters: −$40.1M, a −7884.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$40.9M.

  • Shares outstanding: 68.5M.

  • Trailing P/E: −1.4×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cardiff Oncology, Inc. employs 30 people — $17K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

CRDF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRDFCardiff Oncology, Inc.$73.1M48
TENXTenax Therapeutics, Inc.$70.4M18
MAIAMAIA Biotechnology, Inc.$70.4M27
CSBRChampions Oncology, Inc.$67.8M27
CGTXCognition Therapeutics, Inc.$71.2M34
NMRANeumora Therapeutics, Inc.$71.6M33
MNOVMediciNova, Inc.$72.2M97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cardiff Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRDF news & analysis

Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer

GlobeNewsWire · 27 Oct 2026positive

Cardiff Oncology announced that Leila Alland, MD, has been appointed interim Chief Medical Officer. The company described her as a biopharmaceutical executive with experience leading oncology drug development programs.

Why it matters — The appointment is relevant to CRDF watchers because it changes the company’s interim medical leadership, bringing in an executive with oncology development experience.

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

GlobeNewsWire · 14 Sept 2026neutral

Cardiff Oncology, Inc. and Nerviano Medical Sciences S.r.l. announced an amendment to their 2017 exclusive license agreement. The announcement was made jointly from San Diego and Nerviano, Italy, on September 14, 2026.

Why it matters — CRDF watchers would want to know the terms of the amended license agreement, as it affects the company's rights and obligations under its partnership with Nerviano Medical Sciences.

Cardiff Oncology to Participate in September 2026 Conferences

GlobeNewsWire · 2 Sept 2026neutral

Cardiff Oncology announced that Mani Mohindru, Ph.D. will participate in two conferences in September 2026. The clinical-stage biotechnology company, which focuses on PLK1 inhibition for cancer therapies, made the announcement in a press release dated September 2, 2026.

Why it matters — Conference participation offers investors and analysts opportunities to hear directly from Cardiff Oncology's leadership about the company's clinical-stage programs and strategic direction.

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

GlobeNewsWire · 11 Aug 2026positive

Cardiff Oncology reported its second quarter 2026 results and provided a business update. The company also announced that positive Phase 2 CRDF-004 data, presented in an oral session at ASCO, support advancing 30 mg onvansertib plus FOLFIRI/bevacizumab into a planned registrational program for first-line RAS-mutated metastatic colorectal cancer.

Why it matters — A CRDF watcher would care because the positive data and the planned move into a registrational program represent a key step forward for the company's lead drug candidate in a defined patient population.

FAQ

Frequently asked questions about CRDF stock

What is the CRDF stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Cardiff Oncology, Inc. have a median 12-month price target of $6.75, with estimates ranging from $1.2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRDF stock a buy right now?

Of the 6 analysts covering Cardiff Oncology, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cardiff Oncology, Inc. 48 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRDF?

As at 28 Oct 2026, Cardiff Oncology, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).

Will CRDF stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +640.1% from the last close, and Ticker Nerd's factor model ranks Cardiff Oncology, Inc. 48 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRDF stock forecast for 2030?

No analyst covering Cardiff Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRDF are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $12 over the next 12 months.

How has CRDF stock performed over the past year?

Cardiff Oncology, Inc. returned -59.3% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cardiff Oncology, Inc. do?

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division.

What is the latest news on CRDF?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer". Cardiff Oncology announced that Leila Alland, MD, has been appointed interim Chief Medical Officer. The company described her as a biopharmaceutical executive with experience leading oncology drug development programs.

Company

About Cardiff Oncology, Inc.

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that target Polo-like Kinase 1 (PLK1), a validated oncology pathway involved in cell division. Its lead product candidate, onvansertib, is an oral and selective PLK1 inhibitor being studied in combination with standard-of-care treatments across multiple cancer types. The company’s current clinical programs center on difficult-to-treat solid tumors and hematologic malignancies, including colorectal cancer, prostate cancer, pancreatic cancer, lung cancer, and breast cancer. Cardiff Oncology’s work is aimed at addressing treatment resistance and improving the effectiveness of existing cancer regimens through combination approaches. Headquartered in San Diego, California, Cardiff Oncology operates as a focused oncology drug development company within the broader biotechnology sector.

CEO Dr. Mani Mohindru Ph.D. · 30 employees · United States · https://www.cardiffoncology.com